NXTC

In November 2025, NextCure announced the closing of a $21.5 million PIPE financing. In January 2026, the company provided updates on its ADC pipeline progress and reported a preliminary year-end 2025 cash position, extending its cash runway into the first half of 2027. In March 2026, NextCure provided a business update and reported full-year 2025 financial results, and an abstract for SIM0505 was accepted for the ASCO 2026 meeting. In April 2026, NextCure received Fast Track Designation from the FDA for SIM0505 for the treatment of platinum-resistant ovarian cancer. In May 2026, the company reported its first-quarter 2026 financial results, highlighting the FDA Fast Track designation for SIM0505 and the initiation of a dose optimization study for SIM0505 in gynecologic cancers; Phase 1 dose escalation data for SIM0505 is expected to be presented at ASCO 2026 on June 1, 2026, and trading of NXTC stock was temporarily halted due to volatility.